Customization of dextran-based advanced nanotherapeutics in glioblastoma multiforme management: Promises, progress, and prospects.

Glioblastoma (GBM) is one of the most aggressive and treatment-resistant brain tumors, largely due to the restrictive nature of the blood-brain barrier (BBB). This barrier significantly limits the efficient delivery of therapeutic agents to the tumor site, thereby reducing treatment efficacy. This review evaluates the potential of dextran (Dex)-based nanoparticles (NPs) as an advanced platform for enhancing BBB penetration and enabling targeted GBM therapy. Dex, a biocompatible and biodegradable polysaccharide, offers key advantages including ease of functionalization, high drug-loading capacity, and improved systemic stability. Recent studies demonstrate that Dex-based nanocarriers enhance drug transport across the BBB via receptor-mediated and adsorptive transcytosis mechanisms, resulting in improved accumulation at tumor sites. Furthermore, surface engineering strategies facilitate active targeting of GBM cells, thereby increasing therapeutic efficacy while reducing systemic toxicity. Comparative evidence indicates that Dex-based nanocarriers outperform conventional delivery systems in terms of targeting efficiency, biocompatibility, and tailored drug release. These systems also show potential for co-delivery of multiple therapeutic agents, supporting combination treatment approaches for improved clinical outcomes. Emerging preclinical studies highlight improved survival outcomes and enhanced pharmacokinetic profiles associated with Dex-based nanocarriers, reinforcing their therapeutic relevance. Despite these promising findings, challenges related to large-scale manufacturing, reproducibility, and regulatory approval remain significant barriers to clinical translation. Future research should focus on clinical validation, scalable synthesis approaches, and long-term safety assessment to facilitate successful translation into clinical practice. Overall, Dex-based NPs represent a versatile and highly promising strategy to overcome existing limitations in GBM treatment and advance targeted nanomedicine approaches for brain cancer therapy.